3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
5
Recruiting
2
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Gynecologic
1
Conditions
Neoplasms
2
Fallopian Tube Neoplasms
2
Pathologic Complete Response
1
Ovarian Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Leiomyosarcoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of the Oesophagus
1
Interventions
pembrolizumab
25
Cyclophosphamide
20
Nivolumab
13
Doxorubicin
13
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Exercise
9
atezolizumab
8
Vincristine
8
Rituximab
8
Radiotherapy
8
Prednisone
8
Dexamethasone
8
Bevacizumab
8
venetoclax
7
fludarabine
7
Pemetrexed
7
Fluorouracil
7
Docetaxel
7
Blood Specimen Collection
7
lenvatinib
6
dostarlimab
6
cemiplimab
6
budigalimab
6
Oxaliplatin
6
Cisplatin
6
durvalumab
5
Leucovorin
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms
×
rucaparib
×
Clear all
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts